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Abstract
 
Tumor necrosis factor receptor–associated factor (TRAF)2 is a critical adaptor molecule for tu-
mor necrosis factor (TNF) receptors in inflammatory and immune signaling. Upon receptor
engagement, TRAF2 is recruited to CD40 and translocates to lipid rafts in a RING finger-
dependent process, which enables the activation of downstream signaling cascades including
c-Jun NH
 
2
 
-terminal kinase (JNK) and nuclear factor (NF)-
 
 
 
B. Although TRAF1 can displace
TRAF2 and CD40 from raft fractions, it promotes the ability of TRAF2 activate signaling over
a sustained period of time. Removal of the RING finger of TRAF2 prevents its translocation
 
into detergent-insoluble complexes and renders it dominant negative for signaling. TRAF1
 
 
 
/
 
 
 
dendritic cells show attenuated responses to secondary stimulation by TRAF2-dependent fac-
tors and increased stimulus-dependent TRAF2 degradation. Replacement of the RING finger
of TRAF2 with a raft-targeting signal restores JNK activation and association with the cyto-
 
skeletal protein Filamin, but not NF-
 
 
 
B
 
 
 
activation. These findings offer insights into the
mechanism of TRAF2 signaling and identify a physiological role for TRAF1 as a regulator of
the subcellular localization of TRAF2.
Key words: CD40 • dendritic cell • lipid rafts • NF-
 
 
 
B • JNK
 
Introduction
 
TNF family proteins are essential regulators of the life and
death of hematopoietic cells, bone and mammary gland
homeostasis, and embryonic development (1). Signaling
through TNF receptor (TNFR)
 
*
 
 proteins is mediated in
part by TNFR-associated factor (TRAF) adapter proteins,
which have been shown to activate the transcription factor
nuclear factor (NF)-
 
 
 
B, mitogen-activated protein kinases
(MAPKs), and Src-family kinases (2).
The general domain organization of TRAF proteins, of
which TRAF2 is the archetype, comprises an NH
 
2
 
-termi-
nal zinc-binding domain, specifically a RING finger followed
by several Zn fingers, and a COOH-terminal TRAF do-
main, consisting of a coiled-coil which permits TRAF oli-
gomerization (TRAF-N) and a receptor binding domain
(TRAF-C; references 3 and 4). There are some exceptions
to this scheme, most notably in TRAF1, which has a
COOH-terminal TRAF domain that is highly homolo-
gous to TRAF2, but lacks the RING and all but one of the
Zn fingers. Trimeric TNF family ligands bind to trimerized
TNFR family proteins, dictating a trimeric mode of bind-
ing of TRAFs in which the affinity and avidity of TRAF
proteins for receptor complexes is greatly enhanced (5–8).
Although TRAFs are essential adapters for signaling
through TNFR family proteins, they do not appear to pos-
sess intrinsic enzymatic activity and the precise mechanism
of their action is unknown. It is clear that the TRAF do-
main of TRAF2 is necessary for its direct interactions with
TNFR proteins such as TNFR2, CD40, TRANCE-R,
CD30, and others, as well as interactions with cytoplasmic
 
factors including TRADD, RIP, NIK, ASK1, GCK, c-IAPs,
I-TRAF, TRIP, A20, and others (2). However, expression
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of the TRAF domain alone inhibits signaling by TNF fam-
ily ligands, and mutants of TRAF2 lacking the RING finger
act as dominant negative factors for NF-
 
 
 
B and MAPK ac-
tivation (9, 10). The NH
 
2
 
-terminal RING and Zn fingers
are therefore required for the activation of these cascades.
An emerging theme in cell surface receptor signaling is
detergent-resistant liquid-ordered lipid membrane micro-
domains, or lipid rafts (11, 12). These complexes are resis-
tant to solubilization at low temperatures in nonionic de-
tergents and thus may serve to assemble or exclude various
signaling complex components, which may enhance signal-
ing specificity. Recently, several reports have demonstrated
that CD40 engagement or Epstein-Barr virus LMP1 ex-
pression results in recruitment of CD40 or LMP1, TRAF2,
TRAF3, and several other proteins to lipid rafts, which are
thought to be intrinsic to some of the signaling functions of
CD40 and LMP1 (13–17).
Although most TRAFs are constitutively present in the
cell types in which they are expressed, TRAF1 is absent in
most resting cells (18). Expression of TRAF1 is rapidly up-
regulated in response to NF-
 
 
 
B and AP-1 activation by a
variety of inflammatory mediators, including TNF-
 
 
 
,
CD40L, LPS, and lymphocyte receptors (19, 20). By itself,
TRAF1 does not appear to activate signaling cascades acti-
vated by TRAF2, although it can hetero-oligomerize with
TRAF2 (3) and interact with many of the same receptors
and cytoplasmic proteins as TRAF2 (2). Although the ex-
act physiological role of TRAF1 is unknown, it appears to
positively regulate survival signals mediated by TRAF2 (19,
21, 22). Recently, TRAF1 was found to be a target of cas-
pases, and the resulting cleavage product negatively regu-
lated the antiapoptotic signals of TRAF2 during TNF-
induced cell death (23, 24).
In this report, we examine the role of the translocation
of TRAF2 into detergent-insoluble complexes in the
TRAF2-dependent activation of NF-
 
 
 
B and JNK. In re-
sponse to CD40 stimulation, TRAF2 translocates into lipid
rafts in a RING finger-dependent process, which is re-
quired for kinase activation. TRAF1, when it is up-regu-
lated in response to TRAF2-mediated signals, regulates the
removal of CD40 and TRAF2 from insoluble complexes
and modulates the ability of TRAF2 to mediate sustained
activation of NF-
 
 
 
B and JNK. In dendritic cells (DCs)
with a targeted deletion of the TRAF domain of TRAF1,
we show that maturation by CD40L leads to a loss of solu-
ble TRAF2 and a concomitant reduction in TNF and
CD40L-mediated survival, revealing a physiological role
for TRAF1 in the regulation of TRAF2-dependent signal-
ing. Substitution of the RING finger of TRAF2 with a
lipid raft–targeting dual acylation signal rescues JNK activa-
tion, but not NF-
 
 
 
B activation, suggesting that raft translo-
cation of TRAF2 is necessary and sufficient for JNK activa-
tion, but insufficient for NF-
 
 
 
B activation.
 
Materials and Methods
 
Reagents.
 
Recombinant mouse TNF-
 
 
 
, IL-4, and GM-CSF
were from R&D Systems, LPS (
 
Escherichia coli
 
 055:B5) was from
 
Sigma-Aldrich, soluble hCD8-TRANCE (TRANCE) was puri-
fied from insect cells as described (25), and soluble mCD8-
CD40L (CD40L) was generated in insect cells and supernatant
was used at a 1:200 dilution as described (26).
Abs specific for I
 
 
 
B-
 
 
 
 were from New England Biolabs, Inc.;
TRAF2 (N-19 and C-20), TRAF1 (N-19), Lyn (44), JNK1 (N-
19), MEKK1 (C-22), and ASK1 (H-300) were from Santa Cruz
Biotechnology, Inc.; 
 
 
 
-actin (Ab-1) was from Calbiochem; HA
(12CA5) from Boehringer; the Flag epitope (M2) was from
Sigma-Aldrich; and TRAF6 was provided by Dr. Sankar Ghosh
(Yale University, New Haven, CT).
 
Constructs.
 
Mouse CD40 was cloned by RT-PCR from
whole spleen mRNA and inserted into the pFLAG-CMV1 clon-
ing vector (Sigma-Aldrich). Mouse TRAF2 and T2
 
 
 
87 in
pcDNA3.1 have been described previously (27). To make M/P-
T2
 
 
 
87, complementary oligonucleotides encoding the NH
 
2
 
-ter-
minal 12 residues of Lck (MGCVCSSNPEDD) with appropriate
flanking restriction sites were annealed, digested, and ligated into
the expression vector encoding T2
 
 
 
87 at the 5
 
 
 
 end of T2
 
 
 
87.
ASK1 in pcDNA3 was provided by Dr. James Woodgett (On-
tario Cancer Institute, University of Toronto, Toronto, Canada)
and HA-tagged Filamin (amino acids 1644–2118) was provided
by Dr. Ulrich Siebenlist (National Institute of Allergy and Infec-
tious Diseases, National Institutes of Health, Bethesda, MD).
MEKK1 in pCFL and Flag-tagged mouse TRAF1, TRAF5, and
TRAF6 have been described previously (28). Site-directed mu-
tagenesis of CD40 was performed on the indicated residues by
the Ex-Site method (Stratagene). All constructs were confirmed
by sequencing.
 
DCs.
 
DCs were generated from bone marrow precursors via
a modification of existing protocols (29, 30). Bone marrow pre-
cursors were plated in 24-well tissue culture plates at a density of
10
 
6
 
/ml, 1 ml/well, in medium containing rmGM-CSF (25 ng/
ml) and rmIL-4 (5 ng/ml) for 7 d, with replacement of 800 
 
 
 
l of
medium on days 2 and 4 and the addition of 500 
 
 
 
l of medium
on day 6. On day 7, cells were left alone or stimulated overnight
with CD40L (1:200) or LPS (100 ng/ml). On day 8, cells were
removed for FACS
 
®
 
 analysis, transferred to a new 24-well plate
for restimulation (see below), or transferred into 96-well plates
(10
 
5
 
 cells/well in 200 
 
 
 
l of medium without GM-CSF or IL-4
and the indicated stimuli [TNF-
 
 
 
, 10 ng/ml; CD40L, 1:200; or
TRANCE, 1 
 
 
 
g/ml] in triplicate) for survival assays. Maturation
was assayed by FACS
 
®
 
 analysis of CD86, CD80, and class II ex-
pression, gated on CD11c
 
 
 
 cells on a FACSCalibur™ (Becton
Dickinson). Survival was assayed by FACS
 
®
 
 analysis of propidium
iodide exclusion after 48 h as described previously (25).
 
Cell Stimulation, Transfection, and Analysis.
 
In vitro differenti-
ated DCs were extensively washed to remove exogenous
growth factors, cultured in medium with low serum (0.5% FBS,
2–4 h), then stimulated as indicated. After stimulation, cells
were washed with ice-cold PBS, lysed, and subject to SDS-
PAGE and Western blotting. To control for equal loading of
each time point, the protein concentration of each sample was
determined and samples were normalized for total protein con-
tent before further processing.
293T cells were transfected in 6-well plates by calcium phos-
phate precipitation as described (28). For NF-
 
 
 
B reporter assays,
cells were transfected with the indicated amounts of expression
constructs and mutants along with 75 ng of an NF-
 
 
 
B-luciferase
reporter plasmid and 25 ng of a 
 
 
 
-galactosidase plasmid to control
for transfection efficiency. Transfection amounts were kept con-
stant at 1 
 
 
 
g by addition of empty pFLAG-CMV1 vector. Lu-
ciferase and 
 
 
 
-galactosidase activity was measured as described 
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(28). In vitro JNK assays were performed on cell lysates as de-
scribed (26). All transfection experiments were repeated at least
three times and representative results are shown.
Where indicated, cells were harvested in 1 ml ice-cold PBS,
then lysed in a solution of 150 mM NaCl, 20 mM HEPES (pH
7.0), 10% glycerol, and 0.75% Triton X-100 with protease and
phosphatase inhibitors. For lysis in NP-40, cells were lysed in
HNE buffer (20 mM HEPES, pH 7.0; 150 mM NaCl, 5 mM
EDTA) with 0.5% NP-40 and protease inhibitors. Cell lysates
were incubated on ice for 20–30 min, vortexed extensively, and
centrifuged in a microfuge at maximum speed at 4
 
 
 
 for 10 min.
Soluble fractions were removed and subjected to SDS-PAGE or
immunoprecipitation. Insoluble fractions were washed extensively
in lysis buffer and solubilized via the addition of SDS gel-loading
buffer, vortexing, and boiling for 10 min. Immunoprecipitation
was performed by the addition of an antibody as indicated to the
soluble fraction, rotation at 4
 
 
 
 for 2–3 h, followed by the addition
of 15 
 
 
 
l protein G-sepharose equilibrated in lysis buffer and rota-
tion at 4
 
 
 
 for 1 h. The beads were washed 3
 
 
 
 in lysis buffer con-
taining detergent and once in lysis buffer without detergent. SDS
gel-loading buffer was added and samples were boiled and sub-
jected to SDS-PAGE and Western blotting.
 
Sucrose Density Gradient Centrifugation.
 
293T cells were trans-
fected as indicated in 10-cm tissue culture plates with 4 
 
 
 
g total
DNA. 6 h before harvesting, CD40L (1:200) was added to the
culture medium. Cells were harvested in ice-cold PBS and lysed
in 1 ml of HNE containing 0.25% Triton X-100, incubated on
ice for 30 min, and vortexed extensively. 1 ml of an 80% sucrose
solution in HNE was mixed with the lysate, and this was overlaid
with 2 ml of a 30% sucrose solution in HNE, followed by 1 ml of
a 5% sucrose solution in HNE. The samples were centrifuged in a
Beckman SW55Ti rotor at 200,000 
 
g
 
 overnight at 4
 
 
 
 as described
(15). 0.5 ml fractions were taken from the top of the gradient to
which 250 
 
 
 
l of 2
 
 
 
 SDS gel-loading buffer was added. 30 
 
 
 
l of
each fraction was subjected to SDS-PAGE and Western blotting.
 
Results
 
TRAF1 Increases the Detergent Solubility of TRAF2.
 
Re-
cently, several groups have shown that CD40 engagement
results in translocation of TRAF2 to detergent-resistant
membranes (13–17). As TRAF1 can hetero-oligomerize
with TRAF2 and interact with the TRAF2 binding site of
CD40, we investigated the effect of TRAF1 on the solu-
bility of TRAF2 in nonionic detergent (0.75% Triton
X-100). We cotransfected HEK 293T cells with constant
amounts of plasmids driving the expression of CD40 and
TRAF2, while titrating the amount of TRAF1. In the ab-
sence of TRAF1, a majority of TRAF2 was found in the
insoluble fraction, whereas the addition of TRAF1 resulted
in a dose-dependent redistribution of TRAF2 to the solu-
ble fraction (Fig. 1 A). TNF-
 
 
 
 stimulation for the last 6 h
before harvesting of cells transfected with TRAF2 results in
a similar distribution of TRAF2 to the insoluble fraction,
which is reversed by increasing doses of transfected TRAF1
(Fig. 1 B). As overexpression of TRAF2 can activate sig-
naling independent of receptor engagement, we examined
the solubility of overexpressed TRAF2 over a range of
concentrations. At low concentrations (similar to those
used in Fig. 1, A and B), TRAF2 is predominantly soluble,
consistent with the inability of low concentrations of
 
TRAF2 to self-aggregate and activate signaling. At higher
concentrations of TRAF2 consistent with the ability to in-
dependently activate signaling, an increasing fraction of
TRAF2 is insoluble (Fig. 1
 
 
 
C).
The NH
 
2
 
-terminal zinc-binding RING finger of TRAF2
has been shown to be essential for NF-
 
 
 
B (9) and JNK (10)
Figure 1. TRAF1 regulates the detergent solubility of TRAF2. (A)
293T HEK cells were transfected in 6-well plates with the indicated
amounts of CD40, TRAF1, and TRAF2. Total DNA content was main-
tained constant at 1  g by the addition of empty vector. Cells were lysed
in 0.75% Triton X-100, and soluble (S) and insoluble (I) fractions were
immunoblotted as indicated. After probing with TRAF2 antibodies
(C-20), blots were stripped and reprobed with anti-Flag M2 to detect
TRAF1 and CD40. (B) As in panel A, but without transfection of CD40.
hTNF-  (10 ng/ml) was added to the culture medium 6 h before har-
vesting. (C) As in panel A. TRAF2 was transfected in the amounts indi-
cated. (D) As in panel A, but with 0.1  g of TRAF2 or an NH2-terminal
truncation mutant removing the first 87 residues (comprising the RING
finger) of TRAF2 (T2 87). 0.5  g of TRAF1 was transfected where in-
dicated ( ). (E) As in panel A. (F) 293T cells were transfected with 1.5
 g of TRAF2 or T2 87, 2.5  g of TRAF1, and 1.0  g of CD40 where
indicated. Cells were treated with CD40L 6 h before harvesting then sub-
jected to sucrose gradient density centrifugation as described in Materials
and Methods and immunoblotted as indicated. 
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activation. To determine if the RING finger of TRAF2
mediates translocation into the insoluble fraction, we
cotransfected CD40 and wild-type TRAF2 or TRAF2
with a deletion of the first 87 amino acids (T2
 
 
 
87), which
comprise the RING finger, with or without TRAF1.
T2
 
 
 
87 was found completely in the soluble fraction, re-
gardless of TRAF1 expression (Fig. 1 D). Like TRAF1,
TRAF5 has been shown to hetero-oligomerize with
TRAF2 (31). To determine if TRAF5 can mediate solubi-
lization of TRAF2, we cotransfected CD40, TRAF2, and
TRAF1 or TRAF5. Whereas TRAF1 can mediate solubi-
lization of TRAF2, an equivalent amount of TRAF5 does
not (Fig. 1 E), suggesting a unique role for TRAF1.
To determine if TRAF1 could indeed mediate transloca-
tion of TRAF2 out of lipid rafts under sustained signaling
conditions, we performed sucrose density gradient centrif-
ugation on extracts of cells transfected with CD40,
TRAF2, or T2
 
 
 
87, with or without TRAF1, treated for
the last 6 h before lysis with soluble CD40L. In cells trans-
fected with CD40 and TRAF2, both CD40 and TRAF2
could be found in the low-density raft fractions, comigrat-
ing with the known raft-associated tyrosine kinase Lyn
(Fig. 1 F, top left). However, addition of TRAF1 resulted
in redistribution of both CD40 and TRAF2 out of the raft
fractions (Fig. 1 F, top right). T2
 
 
 
87 was not found in sig-
nificant amounts in the raft fractions with or without
TRAF1, and even in the absence of overexpressed
TRAF1, T2
 
 
 
87 coexpression resulted in a steady-state re-
duction of CD40 in the raft fractions compared with coex-
pression with wild-type TRAF2 (Fig. 1 F, bottom). Al-
though TRAF1 resulted in a complete loss of TRAF2 from
the raft fractions, there was still a considerable amount of
insoluble TRAF2 in the crude cell extract, which may rep-
resent cytoskeleton-associated TRAF2 (Fig. 1 F, “crude
extract” lanes).
 
Differential Effects of TRAF2 and TRAF6 on CD40 Local-
ization.
 
While oligomerization of TRAF2 at the receptor
appears to be necessary for the translocation of TRAF2 and
CD40 into lipid rafts (13), it is unclear whether receptor
engagement per se is sufficient for stable translocation of
the receptor. The cytoplasmic tail of CD40 has two de-
fined TRAF binding sites, one that is proximal to the
membrane to which TRAF6 binds, and a more distal site
which binds to TRAFs 1, 2, 3, and 5 (6). Whereas TRAF2
and TRAF3 have been shown to be recruited to mem-
brane rafts by CD40 engagement in primary cells (14),
TRAF6 does not appear to play a prominent role in
CD40-associated lipid rafts (13).
To compare the contributions of TRAF2 and TRAF6
to CD40 translocation, we generated point mutants of
CD40 that are deficient in binding to TRAF2, TRAF6,
or both. Based on structural studies, we (unpublished data)
and others (6) have identified E239 of mouse CD40 as a
critical binding residue for TRAF6 and Q253 as a critical
binding residue for TRAF2. Cotransfection of CD40 and
alanine mutations of E239, Q253, or both with TRAF2
followed by immunoprecipitation of CD40 demonstrated
that TRAF2 binding to CD40-Q253A is greatly attenu-
ated (Fig. 2 A, top). A similar cotransfection of CD40
constructs with TRAF6 and immunoprecipitation of
TRAF6 demonstrated that TRAF6, but not TRAF2,
binding to CD40-E239A is greatly attenuated (Fig. 2 A,
bottom). Sucrose density gradient fractionation revealed
that wild-type CD40 and CD40-E239A translocated to
raft fractions, but to a greater extent in the presence of
overexpressed TRAF2 than in the presence of overex-
pressed TRAF6. However, CD40-Q253A and the double
E239A/Q253A mutant remained in the soluble fraction in
the presence of overexpressed TRAF2 or TRAF6 (Fig. 2
B). As CD40-WT is found in the raft fraction in the pres-
ence of overexpressed TRAF6 at similar levels to those of
CD40-E239A, raft translocation of CD40 appears to be
dependent on its ability to bind to TRAF2, but not to
TRAF6. Furthermore, a higher level of raft-associated
CD40-E239A than CD40-WT was observed in the pres-
ence of overexpressed TRAF2, which suggests that
TRAF6 binding may actually decrease the steady-state af-
finity of CD40 for the raft fraction.
 
TRAF1 Promotes Sustained TRAF2-mediated Signaling.
 
It has previously been shown that stable expression of
TRAF1 promotes sustained JNK activation by TNF-
 
 
 
(19). We found that, with the transfection of limiting
amounts of TRAF2 (100 ng) and treatment with TNF-
 
 
 
(5 ng/ml) over the final 6 h before cell lysis, increasing
doses of TRAF1 coexpression increased, then decreased
Figure 2. TRAF2 regulates the steady-state detergent solubility of
CD40. (A) 293T cells were transfected with Flag-tagged CD40 constructs
(0.5  g of WT or mutants as indicated) and TRAF2 (0.5  g, top) or
Flag-tagged TRAF6 (0.5  g, bottom). CD40 was immunoprecipitated
with anti-Flag M2 antibodies and immunoprecipitates were probed for
TRAF2 and CD40 as indicated. TRAF6 was immunoprecipitated with
anti-TRAF6 antibodies and immunoprecipitates were probed for CD40
and TRAF6 as indicated. (B) As in Fig. 1 F, but cells were transfected
with CD40-WT or the indicated mutants (1.0  g) and TRAF2 or
TRAF6 (1.5  g) and subjected to sucrose density gradient centrifugation
and immunoblotting. 
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the steady-state level of JNK activation (Fig. 3 A). This
suggests that TRAF1 can either potentiate or inhibit sus-
tained TRAF2-mediated signaling depending on the ratio
of TRAF1 and TRAF2. Short-term treatment by TNF-
 
 
 
(
 
 
 
30 min) induced similar levels of JNK activation in un-
transfected cells or cells transfected with TRAF2 regardless
of the amount of cotransfected TRAF1 (19, and data not
shown). In an NF-
 
 
 
B-luciferase reporter assay, levels of lu-
ciferase activity should reflect the integrated total of NF-
 
 
 
B
activation over the time between transfection and cell lysis.
We found that increasing levels of TRAF1 expression had
little effect on the ability of limiting amounts of CD40 (50
ng) alone to activate NF-
 
 
 
B. However, in the presence of
limiting amounts of TRAF2 (100 ng), TRAF1 overexpres-
sion could increase sustained NF-
 
 
 
B reporter activity (Fig.
3 B). The lack of effect of overexpressed TRAF1 on CD40
alone is likely due to the fact that, in this experimental sys-
tem, endogenous TRAF6 is the predominant mediator of
CD40-induced NF-
 
 
 
B activation and the effect of overex-
pressed TRAF1 on endogenous TRAF2 is masked (un-
published data). Thus, the ability of TRAF2 to mediate the
sustained activation of downstream signal cascades appears
to correlate with its solubility, which is regulated by the ra-
tio of TRAF2 to TRAF1.
 
TRAF1 Recycles TRAF2 for Signaling via Serial Receptor
Engagement in DCs.
 
TRAF1 is not ordinarily expressed at
high levels in nonactivated cells, but it is rapidly upregu-
lated by NF- B activation downstream of TNF family
ligand stimulation (19). Therefore, we hypothesized that
TRAF1 may play a physiological role in situations where
multiple TNF family ligands that signal through TRAF2
engage cells over time. DCs are known to respond to nu-
merous TNF family members throughout their life cycle,
including TNF- , CD40L, and TRANCE. Furthermore,
histological studies have shown that TRAF1 expression is
consistently elevated in DCs (18). Using bone marrow–
derived DCs from wild-type mice and mice with a targeted
deletion of the TRAF domain of TRAF1 (TRAF1 / ;
unpublished data), we found that CD40L or LPS matura-
tion induces comparable levels of CD86 expression on
CD11c  cells (Fig. 4 A), suggesting that TRAF1 is not re-
quired for DC differentiation or maturation. In wild-type
DCs, TRAF1 expression is relatively low in the immature
stage, but is greatly up-regulated by maturation in CD40L
or LPS (Fig. 4 B). Treatment of immature or LPS-matured
DCs from wild-type or TRAF1 /  mice with CD40L in-
duced similar levels of NF- B activation as measured by
I B degradation (Fig. 4 B, lanes 1–2, 5–6, 7–8, and 11–12).
In DCs matured in CD40L, there was a marked deficiency
in NF- B activation by CD40L restimulation in TRAF1 / 
DCs as compared with wild-type DCs (Fig. 4 B, lanes 3–4
and 9–10). Consistent with this deficiency in NF- B acti-
vation, there was substantially less preexisting soluble
TRAF2 in CD40L-matured TRAF1 /  DCs than in
CD40L-matured wild-type DCs (Fig. 4 B, lanes 1 and 3
versus lanes 7 and 9). CD40L restimulation in all cases re-
sulted in similar short-term (20 min) reductions of soluble
TRAF2, consistent with previous observations (14, 16). To
examine the kinetics of I B degradation, we restimulated
wild-type or TRAF1 /  DCs matured in CD40L with
CD40L at intervals up to 2 h (Fig. 4 C). Although the
magnitude of the response of TRAF1 /  DCs was blunted,
the kinetics of I B degradation and resynthesis at 2 h were
similar to those of wild-type DCs. In this experiment, we
lysed cells in 1% SDS to examine total cellular levels of
TRAF2. Interestingly, after CD40L maturation, total cellu-
lar TRAF2 was substantially lower in TRAF1 /  DCs than
in wild-type DCs. Total cellular TRAF2 levels in wild-
type cells did not decrease in response to CD40L restimula-
tion, suggesting that TRAF1 may protect TRAF2 from
activation-induced degradation. As mature DCs do not
demonstrate strong JNK activation in response to CD40L
or TNF-  (unpublished data), we did not examine JNK
activation in TRAF1 /  DCs. However, CD40L and
TNF- -mediated JNK activation upon restimulation in B
cells previously activated by CD40L was deficient in
TRAF1 / , but not wild-type B cells (unpublished data).
Once mature, DCs quickly undergo apoptosis in the ab-
sence of survival stimuli provided by activated T cells in-
cluding TNF family ligands such as TNF- , CD40L, and
TRANCE (32). We found that TRAF1 /  DCs matured
in CD40L display severely impaired survival in response to
TNF-  stimulation and partially impaired survival in re-
sponse to CD40L, with a negligible defect in TRANCE-
mediated survival. TRAF1 /  DCs matured in LPS, which
does not signal through TRAF2, had comparable survival
responses to wild-type DCs under stimulation by TNF- ,
CD40L, and TRANCE (Fig. 4 D). Thus, TRAF1 appears
Figure 3. TRAF1 promotes sustained TRAF2-mediated JNK and
NF- B activation. (A) 293T cells were transfected with TRAF2 (100 ng)
and TRAF 1 (0, 33, 100, 300, or 900 ng, indicated by broadening line) as
indicated. 6 h before harvesting, 10 ng/ml TNF-  was added to the cul-
ture medium. Cells were lysed in 0.75% Triton X-100 and subjected to
an in vitro JNK kinase assay. (B) 293T cells were transfected with varying
amounts of TRAF1 (0, 100, or 500 ng, indicated by broadening line),
CD40 (50 ng), and TRAF2 (100 ng) as indicated and subjected to an
NF- B reporter assay. Values are indicated as fold increase over back-
ground, and are normalized against an internal standard ( -galactosidase).928 TRAF1 Regulates TRAF2 Signaling
to be dispensable for the first TRAF2-dependent signal
(CD40L-induced maturation), but its up-regulation by the
maturation signal maintains high levels of soluble TRAF2,
enabling subsequent TRAF2-dependent signals (TNF-  or
CD40L-induced survival) to occur. Although TRANCE
can activate NF- B through TRAF2 in vitro (28), it pre-
dominantly signals through TRAF6 (28, 33), which may
explain the negligible difference in survival observed in
CD40L-matured wild-type and TRAF1 /  DCs.
Raft Translocation of TRAF2 Is Necessary and Sufficient for
JNK, but Not NF- B Activation. As the RING finger of
TRAF2 is necessary for NF- B and JNK activation, as well
as for raft translocation, we investigated whether raft trans-
location is sufficient for the ability of TRAF2 to activate
these signals. Many Src-family kinases are acylated, leading
to their accumulation in membrane rafts (11). We gener-
ated cDNA encoding the myristoylation-palmitoylation
signal from Lck linked to the NH2 terminus of T2 87 (M/
P-T2 87), thus directing redistribution of T2 87 to the
membrane raft fraction in a RING finger-independent
manner. When overexpressed with or without CD40 and/
or TRAF1, M/P-T2 87 was localized primarily in the in-
soluble fraction, although coexpression of TRAF1 could
redistribute a small amount of M/P-T2 87 to the soluble
fraction (Fig. 5 A, top). Analysis of M/P-T2 87 by sucrose
density gradient centrifugation showed that it was predom-
inantly localized to raft fractions, although coexpression of
TRAF1 could redistribute a small amount of M/P-T2 87
to soluble fractions (Fig. 5 A, bottom). M/P-T2 87 could
not substantially activate NF- B (Fig. 5 B). However, in a
JNK assay, overexpressed M/P-T2 87 was able to rescue
the deficiency in JNK activation by T2 87, although only
about half as efficiently as wild-type TRAF2 (Fig. 5 C).
The incomplete rescue of JNK activity may be due to
over-efficient raft targeting by M/P-T2 87. This bifurca-
tion of the ability to activate JNK and NF- B indicates that
the RING finger’s ability to mediate raft translocation is
necessary and sufficient for JNK activation. However, raft
translocation is not sufficient to activate NF- B, suggesting
that the RING finger has an essential function in addition
to raft translocation that is required for NF- B activation.
As it has been suggested that the RING finger of
TRAF2 is necessary to associate with the MAP3K
MEKK1 (34), which may be, in turn, necessary for JNK
activation (35), we tested the ability of M/P-T2 87 to in-
duce the translocation of MEKK1 to detergent-resistant
membranes. Coexpression of wild-type TRAF2, T2 87,
and M/P-T2 87 with MEKK1 and lysis in 0.75% Triton
X-100 showed that the ability of TRAF2 to mediate trans-
location of MEKK1 into the insoluble fraction correlated
with its ability to activate JNK. Wild-type TRAF2 and
M/P-T2 87 induced the translocation of MEKK1, but
T2 87 did not (Fig. 5 D, top). The apparent necessity of
the RING finger for association with MEKK1 actually re-
Figure 4. TRAF1 /  DCs have  deficient
secondary responses to TRAF2-dependent sig-
nals. (A) Wild-type and TRAF1 /  (T1 / )
DCs were matured by overnight culture in
CD40L (1:200) or LPS (100 ng/ml) and CD86
expression was monitored by FACS® analysis.
Immature cells are shown as shaded areas on
the histogram and matured cells are shown as
broad dark lines. (B) DCs were matured as in
panel A (immature, lanes 1–2 and 7–8; CD40L
matured, lanes 3–4 and 9–10; LPS matured,
lanes 5–6 and 11–12), starved in medium con-
taining 0.5% serum for 2 h, and restimulated
with CD40L (1:200) as indicated for 20 min
(even numbered lanes; odd numbered lanes
were not restimulated). Cells were lysed and
the soluble fractions were immunoblotted as
indicated. Ratios of soluble TRAF2 relative to
the level of soluble TRAF2 in unstimulated
immature cells were determined by densitome-
try and normalized to  -actin levels, and are in-
dicated below the  -actin blots. (C) DCs were
matured in CD40L and starved as in B, then
restimulated with CD40L as indicated. Cells
were lysed in 1% SDS to solubilize total cellular
protein and immunoblotted as indicated. Akt
levels are shown as a loading control. (D) DCs
prepared as in panel A were incubated in nor-
mal medium, or medium containing TNF- 
(10 ng/ml), CD40L (1:200), or TRANCE (1
 g/ml) for 48 h as indicated. Survival was de-
termined by PI exclusion FACS®. Specific res-
cue is represented as (% of surviving cells [stim-
ulated]   % of surviving cells [unstimulated])/
([100   % of surviving cells [unstimulated]).929 Arron et al.
flects a requirement for lipid raft translocation but not the
physical presence of the RING finger. Thus, as MEKK1
was previously shown to interact with a TRAF2 fusion
construct with the COOH-terminal TRAF domain re-
placed by FKBP (34), it appears that MEKK1 interacts
with the Zn fingers of TRAF2, and this interaction is de-
pendent upon the ability of TRAF2 to translocate to lipid
rafts. ASK1, another MAP3K known to interact with
TRAF2 and activate JNK, interacts with the TRAF do-
main of TRAF2. Unlike MEKK1, the association of ASK1
and TRAF2 is not dependent on the RING finger of
TRAF2 (36). ASK1 did not translocate to detergent-resis-
tant membranes upon coexpression with TRAF2 (Fig. 5
D, bottom).
Raft Translocation Is Necessary for the Interaction of TRAF2
with the Actin-binding Protein Filamin. Some TRAF pro-
teins have been shown, upon activation, to localize to the
actin cytoskeleton (15), potentially mediated through bind-
ing to Filamin (37). Furthermore, although nearly all of the
known interactions TRAF2 has with other proteins appear
to be mediated through the TRAF-C domain, it was pro-
posed that TRAF2 interacts with Filamin through its
RING finger domain (37). The presence of nonraft-associ-
ated, insoluble TRAF2 but not T2 87 in crude extracts
(Fig. 1 F) led us to investigate whether raft translocation
was necessary for binding to cytoskeletal components. We
cotransfected Filamin with TRAF2, T2 87, or M/P-
T2 87 in the presence or absence of TRAF1. We found
that lysis in 0.5% NP-40 more efficiently dissociated M/P-
T2 87 from membrane rafts than 0.75% Triton X-100 for
coimmunoprecipitation purposes. Immunoprecipitation of
Filamin and Western blotting revealed that M/P-T2 87
could interact with Filamin as efficiently as wild-type
TRAF2, while nonacylated T2 87 could not (Fig. 6, left
side). Thus, it appears that, as in the case of MEKK1 (Fig. 5
D), the RING finger is not essential for physical interaction
of TRAF2 and Filamin, but raft translocation, ordinarily
mediated by the RING finger, is necessary for Filamin
binding. Furthermore, TRAF1 was able to compete for
binding to Filamin with TRAF2, thus in the presence of
overexpressed TRAF1, TRAF2 did not bind to Filamin
(Fig. 6, right side). This suggests that sequestration into the
cytoskeleton by Filamin may serve to inactivate TRAF2 af-
ter it has translocated into membrane rafts, thus down-reg-
Figure 5. Forced raft  localization of
TRAF2 is sufficient to activate JNK, but not
NF- B. (A) Top, 0.1  g of wild-type
TRAF2 (wt), T2 87, or T2 87 with an
NH2-terminal myristoylation-palmitoylation
signal peptide (M/P-T2 87) was cotrans-
fected with or without TRAF1 ( , 0.5  g),
with or without CD40 ( , 0.2  g) as indi-
cated. Soluble and insoluble fractions were
prepared as in Fig. 1. The relative proportion
of soluble vs. insoluble TRAF2 or its mutants
in a given lane was determined by densitome-
try (pixel density [PD]sol/PDsol PDinsol) and is
indicated below the immunoblots (note: this
is a reflection of values relative to one an-
other, but does not provide an absolute mea-
sure of solubility). (Bottom) Cells were trans-
fected with M/P-T2 87, CD40, and  / 
TRAF1 and subjected to sucrose density gra-
dient centrifugation as in Fig. 1 F. (B) Cells
were transfected with the indicated TRAF2
constructs (0.4  g) and subjected to an NF- B
reporter assay as in Fig. 3 B. (C) Cells were
transfected as in B and subjected to an in vitro
JNK assay as in Fig. 3 A. (D) Cells were trans-
fected with the indicated TRAF2 constructs
(0.3  g) and MEKK1 or ASK1 (0.3  g) as in-
dicated and soluble and insoluble fractions
were prepared and immunoblotted.
Figure 6. Interactions with TRAF2 and the actin-binding protein Fil-
amin are dependent on raft translocation of TRAF2. Cells were trans-
fected as indicated with HA-tagged Filamin (amino acids 1644–2118; 0.3
 g), TRAF2 constructs (0.3  g), and TRAF1 (0.3  g) as indicated.
Upon harvesting, cells were lysed in 0.5% NP-40, subjected to immuno-
precipitation of Filamin with antibodies against HA, and immunoblotted
as indicated.930 TRAF1 Regulates TRAF2 Signaling
ulating sustained or repeated TRAF2 signaling by internal-
ization and possible degradation (16). By preventing
TRAF2 from interacting with Filamin, most likely due to a
greater affinity for Filamin, TRAF1 may therefore prolong
and enhance TRAF2-mediated signaling.
Discussion
The data presented in this report reconcile widely vary-
ing observations about TRAF2 signaling to provide a
potential mechanism of TRAF2’s action. First, the mecha-
nism of TRAF2 signaling centers on its ability to trans-
locate to lipid rafts. The NH2-terminal RING finger do-
main of TRAF2 is necessary both for TRAF2’s ability to
activate signaling cascades and to translocate to lipid rafts.
Enforced raft translocation of TRAF2 lacking its RING
finger (T2 87) rescues T2 87’s ability to activate JNK, but
not NF- B. Second, under conditions of sustained stimula-
tion through TRAF2-dependent receptors, TRAF2 be-
comes mostly insoluble and total cellular TRAF2 decreases.
Third, TRAF1 is known to be upregulated by activation of
NF- B and AP-1, often in TRAF2-dependent signaling.
TRAF1 can displace TRAF2 from rafts and promote sus-
tained TRAF2-mediated signaling in response to a single
stimulus or multiple stimuli over time. Thus, a dynamic
model emerges of translocation of the receptor complex
mediated by TRAF2, which is likely to be the trigger for
signal activation in response to a stimulus. A physiological
role for TRAF1 is to “reset” the system by dissociating
TRAF2 from insoluble complexes, rescuing it from degra-
dation, and enabling subsequent stimuli to transduce signals
through TRAF2.
The Roles of Raft Translocation and the RING Finger
in TRAF2 Signaling. Prior reports have suggested that
CD40 translocates to rafts upon ligand engagement and
this leads to binding of TRAF proteins (13, 14). In agree-
ment with the potential requirement for zinc binding abil-
ity for TRAF2 to translocate to rafts (13), we have found
that TRAF2 requires its NH2-terminal RING finger do-
main to translocate to the insoluble fraction (Fig. 1). Nev-
ertheless, a mutant of TRAF2 lacking the RING finger,
T2 87, is fully capable of binding to CD40 and acting as a
dominant-negative for TRAF signaling (9, 10). Further-
more, we have found that T2 87 overexpression actually
reduces the amount of raft-associated CD40 (Fig. 1 F), so
the TRAF domain of TRAF2 can clearly interact with
CD40 in the detergent-soluble fraction. Although short-
term stimulation of a CD40 mutant that cannot bind to
TRAF2 resulted in its apparent translocation to lipid rafts
(13), our data show that steady-state residence in lipid rafts
by CD40 is dependent on its ability to bind to TRAF2
(Fig. 2). This suggests that the ability to activate down-
stream signals upon binding to a receptor is tied to the
ability of TRAF2 to translocate the receptor complex to
lipid rafts.
It is thought that the NH2-terminal domain of TRAF2
somehow activates kinases that lead to NF- B and MAPK
signaling. However, with the exception of MEKK1 (34),
all of the kinases known to interact with TRAF2 interact
with the COOH-terminal receptor-binding domain (2).
Our data suggest that MEKK1 does not physically associate
with the RING finger of TRAF2 since enforced raft trans-
location of M/P-T2 87 induces JNK activation and trans-
location of MEKK1 (Fig. 5). This apparent discrep-
ancy may be explained by the observation that wild-type
TRAF2 did not interact with MEKK1 until TNF-  stim-
ulation (34). TNF-  stimulation likely induced the trans-
location of TRAF2 to lipid rafts, where it may have had
better access to MEKK1 or to intermediary proteins link-
ing TRAF2 to MEKK1. Taken together with observations
by the same authors that a construct with replacement of
the TRAF-C domain of TRAF2 with an inducible multi-
merization signal could interact with and activate MEKK1,
our data suggest that TRAF2 interacts with MEKK1 not
via its RING finger, but via its Zn fingers, but can only do
so upon raft translocation, which is dependent on the
RING finger. Regardless, the importance of MEKK1 in
TNF- –mediated JNK activation is disputable, as genetic
deletion targeting different regions of MEKK1 has shown
opposite results with regard to its role in TNF-mediated
JNK activation (35, 38). TRAF2 did not induce the trans-
location of ASK1, which is known to interact with the
TRAF domain of TRAF2 in the soluble fraction (34).
This interaction is independent of the RING finger of
TRAF2, thus it does not depend on translocation. There-
fore, all of the known protein–protein interactions medi-
ated by TRAF2 appear to be via the COOH-terminal re-
ceptor-binding TRAF domain or Zn fingers, but not the
RING finger. This favors a model wherein receptor en-
gagement by a ligand recruits TRAF2 and cytoplasmic fac-
tors including MAP3Ks such as ASK1, first in the deter-
gent-soluble fraction. Subsequently, the RING finger
mediates translocation of the transmembrane receptor
complex to lipid rafts, which may simultaneously activate
and release the kinases in a concerted mechanism, the de-
tails of which are still unclear.
TRAF1 Rescues TRAF2 from Insolubility and Degrada-
tion. Although the ability of TRAF2 to translocate to rafts
appears to be tied to its ability to activate signal cascades,
we have found that in primary cells under circumstances of
sustained receptor engagement ( 16 h) in the absence of
TRAF1, the steady-state level of TRAF2 decreases and
TRAF2-dependent receptors become refractory to further
stimulation (Fig. 4). Others have demonstrated that, under
short-term periods of signaling ( 1 h), TRAF2 becomes
insoluble and degrades in response to CD40 (16) and
CD30 engagement (39). Stimulation of TNFR2 has re-
sulted in a depletion of soluble TRAF2, potentiating
TNFR1-mediated cell death (40). Thus, while transloca-
tion into lipid rafts is essential for TRAF2 to activate sig-
naling processes, once translocated, it appears that a given
complex of TRAF2 is inactivated and subsequently de-
graded, thus supporting the idea that translocation and
kinase activation are concerted, instantaneous processes.
TRAF1, however, is able to displace TRAF2 away from
the insoluble fraction back into the cytosolic fraction and931 Arron et al.
protect it from degradation. The mechanism of how this
happens is unclear, but it is possible that TRAF1 hetero-
oligomerizes with TRAF2, displacing it from insoluble
complexes, and/or it competes with TRAF2 for binding
sites on the receptor. In support of this, in transient trans-
fection assays where TNF-  stimulation or overexpression
of CD40 and TRAF2 simulates prolonged stimulation,
TRAF1 increases the solubility of TRAF2, which increases
JNK and NF- B activation at lower levels of TRAF1. In
the presence of excessive TRAF1, sustained TRAF2-depen-
dent signaling decreases, which may be a result of excessive
TRAF1 trapping TRAF2 in soluble complexes outside
of lipid rafts and/or competing for receptor binding sites
(Fig. 3). Thus, TRAF1 up-regulation by TRAF2-inde-
pendent signals (e.g., lymphocyte receptor stimulation)
may in fact result in the inhibition of TRAF2-mediated
signaling, such as that observed by Tsitsikov et al. (41). The
presence of considerable amounts of TRAF2 in insoluble
complexes that are not raft-associated (Fig. 1 F) indicates
that there may be another subcellular location of insoluble
TRAF2 complexes. TRAF2 has been shown to interact
with Caveolin-1 (42) and the actin-binding protein Fil-
amin (37; Fig. 6) and has been suggested to accumulate in
perinuclear (43) or cytoskeletal compartments after signal-
ing (15). This may ultimately lead to degradation of
TRAF2 (16, 39). During the preparation of this paper, sev-
eral mechanistic studies have shown that TNFR2 and
CD40 receptor engagement indeed leads to RING finger-
dependent translocation, ubiquitination, and degradation of
TRAF2 (44–46). Given TRAF2’s association with lipid
rafts and caveolae, a reasonable model suggests that, upon
receptor engagement, TRAF2 first translocates to mem-
brane rafts, where it can activate kinase cascades. It then
may be internalized via caveolae, whereupon it is trafficked
to cytoskeletal compartments and degraded. As we found
that only TRAF2 that is capable of raft translocation can
bind to Filamin and that TRAF1 can disrupt the interac-
tion of TRAF2 and Filamin (Fig. 6), it appears that cyto-
skeletal trafficking of TRAF2 is a consequence of raft trans-
location. Furthermore, it is likely that TRAF1 influences
the intracellular trafficking of activated TRAF2 by solubi-
lizing it not only from lipid rafts, but also from cytoskeletal
structures. This may, in turn, prevent or reduce the degra-
dation of activated TRAF2 complexes, thereby increasing
the available levels of soluble TRAF2 for subsequent sig-
naling by engagement of multiple TNF receptor family
proteins over time (Fig. 4).
The Physiological Function of TRAF1 in DC Survival.
To determine if TRAF1 can indeed modulate TRAF2-
dependent signaling in a physiologically relevant situation
consistent with our biochemical findings from overexpres-
sion experiments, we examined the role of TRAF1 in
DCs. As TRAF1 is up-regulated by signals such as CD40L
and LPS that influence DC maturation, and as mature DCs
respond to TRAF2-dependent factors such as TNF- ,
CD40L, and TRANCE for their survival, DCs should pro-
vide a physiological window into the functions of TRAF1
and TRAF2 that we have defined biochemically.
The role of TNF family ligand signaling in DC homeo-
stasis is well documented. DCs residing in peripheral tis-
sues become activated by the presence of inflammatory
mediators, including IL-1, LPS, and TNF- , or the pres-
ence of activated T cells, which may express TNF- ,
CD40L, or TRANCE (47). The spontaneous apoptosis of
mature DCs in the absence of survival stimuli provided by
activated T cells appears to be at least partially due to auto-
crine activation of TNFR1 leading to caspase activity, as
TNFR1 /  DCs in culture are highly resistant to sponta-
neous apoptosis (48).
In this study, in TRAF1 /  DCs, CD40 signaling in
the short term (up to 20 min) on immature cells is intact
and comparable to that of wild-type cells, enabling NF-
 B activation and functional maturation, as well as deple-
tion of TRAF2 from the soluble fraction (Fig. 4). As the
signaling and functional outcomes in immature wild-type
and TRAF1 /  DCs are similar, and as immature wild-
type DCs express low levels of TRAF1, it is likely that the
initial stimulation is TRAF1 independent. However, after
24 h of stimulation by CD40L and a brief starvation pe-
riod followed by restimulation, there is a marked differ-
ence between wild-type and TRAF1 /  cells. Despite
similar CD40L-dependent induction of CD40 expression
in wild-type and TRAF1 /  DCs (unpublished data),
CD40L can reactivate NF- B in wild-type cells, but NF-
 B activation in TRAF1 /  cells is markedly attenuated.
This correlates directly with the level of preexisting
TRAF2. As TRAF1 can dissociate CD40 in addition to
TRAF2 from insoluble complexes (Fig. 1 F), it is possible
that CD40 can also be trapped in nonsignaling raft com-
plexes in TRAF1 /  DCs. These signaling events corre-
late strongly with substantially reduced DC survival medi-
ated by TRAF2-dependent factors TNF-  and CD40L in
TRAF1 /  DCs matured in CD40L compared with
those matured in LPS, a TRAF2-independent factor. In
TRAF1 /  DCs matured in CD40L, TNF-  provided
virtually no survival effect, while CD40L was able to pro-
mote survival, albeit to a lesser extent than in wild-type
DCs, and TRANCE promoted similar survival levels.
This is consistent with the fact that TRAF2 is the pre-
dominant TRAF protein that mediates survival signaling
downstream of TNFR1 and TNFR2, while CD40 and
TRANCE-R can signal through TRAF6 as well as
through TRAF2 (6, 28). Given that TRAF1 is highly ex-
pressed in DCs (18) and it regulates the availability of
TRAF2 for antiapoptotic signaling, it is likely that the
balance between caspase activation and pro-survival sig-
nals is regulated to some extent by TRAF1 in DCs. This
hypothesis is consistent with our finding in TRAF1 / 
DCs that maturation of DCs by CD40L tilts the balance
of TNF-  signaling from survival to apoptosis due to a
depletion of soluble TRAF2.
TRAF1 Modulates TRAF2 Signaling. The implications
of TRAF1’s ability to regulate the solubility of TRAF2 in
order to modulate signaling outcomes are supported by
several studies. Previously, we have found that transgenic
overexpression of TRAF1 in T cells leads to prolonged932 TRAF1 Regulates TRAF2 Signaling
survival of activated CD8  T cells that may otherwise be
subject to TNF- –induced apoptosis (22). Others have
shown that TRAF1, in concert with TRAF2, c-IAP1, and
c-IAP2, contributes to the suppression of TNF-  induced
caspase-8 activation and subsequent cytoprotection (21). In
stable transfectants overexpressing full-length TRAF1, but
not in transfectants expressing an NH2-terminal truncation
of TRAF1, NF- B, and JNK activation was sustained (19).
It has been observed that TRAF1 is a target of caspases
during apoptosis, which results in a decrease in its cytopro-
tective properties and a concomitant decrease in sustained
antiapoptotic signaling by TRAF2 (23, 24). The increased
TNF-induced skin necrosis observed in a recent report of
TRAF1 /  mice (41) is reminiscent of the “feed-forward”
TNF-induced TNF overproduction in TRAF2 /  cells
(49). As TNFR1 activates TRAF2-independent pathways
in addition to TRAF2-dependent pathways, it is possible
that the loss of TRAF1 favors TRAF2-independent signal-
ing. Thus, although TRAF1 may appear to have a negative
role in TRAF2-independent TNF signaling, our results in-
dicate that TRAF1 can be a positive regulator of TRAF2-
dependent signaling.
Conclusion. Although previous reports have concluded
that TRAF signaling takes place within the rafts, our re-
sults suggest a slightly altered model (Fig. 7). As the recep-
tor, TRAF2, and downstream signaling components can
interact in soluble lysates, and especially as T2 87 cannot
translocate to rafts but can still interact with both the re-
ceptor and downstream components, it appears that the
act of translocation is coupled to the activating event.
Thus, upon receptor engagement, the transmembrane re-
ceptor, TRAF2, and downstream signaling molecules as-
semble in the detergent-soluble fraction. Subsequently,
TRAF2 translocates with the receptor to lipid rafts, simul-
taneously releasing and activating the downstream kinase.
It is unclear what the exact mechanism of activation of the
downstream kinase is, but it is possible that the colocaliza-
tion of TRAF2 and downstream kinases in the raft mi-
croenvironment and/or raft-associated kinases such as
c-Src either directly or indirectly activate these kinases.
TRAF2 is now sequestered in the rafts, unable to stimu-
late additional molecules of downstream kinases. As
TRAF2 interacts with the actin-binding protein Filamin,
which is a raft translocation-dependent process (Fig. 6), it
is possible that TRAF2 and/or other components of the
receptor complexes are internalized and possibly degraded.
As a result of this initial signaling, NF- B and AP-1 are
activated and TRAF1 gene expression is up-regulated.
TRAF1 protein levels rise, and now TRAF1 can recycle
TRAF2 into the soluble cytoplasmic fraction and poten-
tially protect it from degradation, where it can reassemble
receptor signaling complexes and continue the cycle. This
allows for what appears to be “sustained” signaling or re-
stimulation through the same receptor, or stimulation
through multiple TNFR family proteins that bind to
TRAF2 over time.
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Figure 7. Proposed model of
the mechanism of TRAF2 sig-
naling and its regulation by
TRAF1. Upon ligand engage-
ment, a TNFR family protein
recruits TRAF2 and various ki-
nases via the COOH-terminal
TRAF domain of TRAF2. The
transmembrane receptor com-
plex assembles in the detergent-
soluble fraction. Upon complex
assembly, the NH2-terminal
RING finger of TRAF2 medi-
ates translocation of the receptor
complex into detergent-resistant
lipid rafts. This translocation
event simultaneously activates
and releases the kinases, while
isolating TRAF2 in an insoluble
complex that may be internal-
ized and/or degraded. The acti-
vated kinases ultimately activate
transcription factors such as
NF- B and AP-1, which up-
regulate the expression of
TRAF1. TRAF1 then releases
TRAF2 from insoluble complexes by hetero-oligomerization with TRAF2 or competing for receptor binding sites. This results in an increase of soluble
TRAF2 that is available for subsequent signaling events mediated by other TRAF2-dependent TNFR family proteins.933 Arron et al.
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